ArticleClinical Medicine Insights. Oncology2013
Targeted therapies in the treatment of advanced hepatocellular carcinoma.
Article in Clinical Medicine Insights. Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Core-Shell Microspheres Prepared Using Coaxial Electrostatic Spray for Local Chemotherapy of Solid Tumors.Pharmaceutics · 2023Article
- A small library of chalcones induce liver cancer cell death through Akt phosphorylation inhibition.Scientific reports · 2020Article
- Review
- Nonalcoholic Lipid Accumulation and Hepatocyte Malignant Transformation.Journal of clinical and translational hepatology · 2016Review
- Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy.Cellular and molecular gastroenterology and hepatology · 2015Article
- Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study.Liver international : official journal of the International Association for the Study of the Liver · 2015Observational
- Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Review
- Tamibarotene: a new hope for therapeutic efficacy in hepatocellular carcinoma patients.Hepatology international · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the most common liver cancer and the third leading cause of cancer death. It has been a major worldwide health problem with more new cases being diagnosed each year. The current available therapies for patients with advanced HCC are extremely limited. Therefore, it is of great clinical interests to develop more effective therapies for systemic treatment of advanced HCC. Several promising target-based drugs have been tested in a number of clinical trials. One breakthrough of these efforts is the approved clinical use of sorafenib in patients with advanced HCC. Targeted therapies are becoming an attractive option for the treatment of advanced HCC. In this review, we summarize the most recent progress in clinical targeted treatments of advanced HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.